Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMORTAL: Pembrolizumab +/- SBRT in Metastatic Urothelial Cancer
NCT04936230Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Nov 2022
- Primary completion
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in urothelial carcinoma (UC), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate at 6 months. Started Nov 2022; status: terminated.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04936230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04936230.